Maana and Aramco Trading Company Launch AI Application to Optimize Maritime Fleet and Shipping Operations
2.3.2021 17:00:00 EET | Business Wire | Press release
Aramco Trading Company (ATC) and Maana today announced the launch of Fanar, the first Artificial Intelligence (AI)-driven maritime fleet optimization application on Microsoft Azure purpose-built for the oil and gas industry.
Fanar combines the expertise of ATC and the Maana Q knowledge technology. It unifies maritime fleet optimization, planning, management and shipment scheduling on a single platform. The application:
- systematically integrates all data sources, constraints, and business rules
- automatically optimizes schedules across the fleet with a single click
- rapidly processes “what if” scenarios for better insights
- dynamically incorporates historic performance to generate new predictions
Fanar has been tested daily by ATC since June 2020.
“Collaboration between Maana and Microsoft helps us, through Fanar, to drive down costs,” said Ibrahim Q. Al Buainain, President and CEO of Aramco Trading Company. “Fanar enables us to optimize all local decisions across our maritime shipping and logistics workflows.”
Based on any given a set of cargoes and fleet of vessels, Fanar can determine how to ship the cargo in a way that minimizes cost, optimizes fleet utilization and maximizes business value. It continuously computes dynamic criteria such as vessel locations and actuals; terminals and ports status and congestion; bunkering locations, costs and quality; vessel cleaning; time and spot chartering costs; weather; risk of piracy, terrorism or war; risk of labor and social unrest resulting in closures; epidemics; shipping routes; canal fees; charter party specifications; Contracts of Affreightment (COA); commodity prices; special considerations; business rules and more.
“Under the hood of Fanar is the digital twin of ATC’s global maritime operations,” said Babur Ozden, founder and CEO of Maana. “It is the largest digital twin in the world on Microsoft Azure for global maritime shipments of oil and gas, holding the history, present state and future simulations of billions of barrels of petroleum products, thousands of voyages and vessels.”
“Maana is a founding technology member of Energy Core, a global Microsoft initiative dedicated to digital transformation in the energy sector, through the power of artificial intelligence and cloud technologies,” said Darryl Willis, Corporate Vice President of Energy at Microsoft. “Fanar is a great example of how Maana and ATC are using Microsoft Azure for supply chain optimization.”
The Fanar application is available to Azure customers. For more information, please contact Fanar@maana.io
About Aramco Trading Company
Aramco Trading Company (ATC) is a wholly owned subsidiary of Saudi Aramco and is responsible for handling Saudi Aramco’s domestic and international supplies to worldwide markets. ATC’s mission is to integrate Saudi Aramco’s global Downstream assets to maximize profitability while ensuring Saudi Aramco’s systems are optimized and reliably balanced.
About Maana
Maana organizes human expertise, enterprise knowhow and industrial data into digital knowledge to assist subject matter experts at critical operation affecting the global economy.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005116/en/
Contact information
Mandi Browning
mandi@maana.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom